Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

P-Glycoprotein Increases Portal Bioavailability of Loperamide in Mouse by Reducing First-Pass Intestinal Metabolism

Matthew B. Dufek, Beverly M. Knight, Arlene S. Bridges and Dhiren R. Thakker
Drug Metabolism and Disposition March 2013, 41 (3) 642-650; DOI: https://doi.org/10.1124/dmd.112.049965
Matthew B. Dufek
Division of Molecular Pharmaceutics (M.B.D., B.M.K.) and Division of Pharmacotherapy and Experimental Therapeutics (D.R.T.), UNC Eshelman School of Pharmacy; and Department of Pathology and Laboratory Medicine, School of Medicine (A.S.B.), The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beverly M. Knight
Division of Molecular Pharmaceutics (M.B.D., B.M.K.) and Division of Pharmacotherapy and Experimental Therapeutics (D.R.T.), UNC Eshelman School of Pharmacy; and Department of Pathology and Laboratory Medicine, School of Medicine (A.S.B.), The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arlene S. Bridges
Division of Molecular Pharmaceutics (M.B.D., B.M.K.) and Division of Pharmacotherapy and Experimental Therapeutics (D.R.T.), UNC Eshelman School of Pharmacy; and Department of Pathology and Laboratory Medicine, School of Medicine (A.S.B.), The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dhiren R. Thakker
Division of Molecular Pharmaceutics (M.B.D., B.M.K.) and Division of Pharmacotherapy and Experimental Therapeutics (D.R.T.), UNC Eshelman School of Pharmacy; and Department of Pathology and Laboratory Medicine, School of Medicine (A.S.B.), The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 41 no. 3 642-650
DOI 
https://doi.org/10.1124/dmd.112.049965
PubMed 
23288866

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Received November 5, 2012
  • Accepted January 3, 2013
  • Published online February 15, 2013.

Article Versions

  • Earlier version (January 3, 2013 - 08:42).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Matthew B. Dufek1,
  2. Beverly M. Knight,
  3. Arlene S. Bridges, and
  4. Dhiren R. Thakker
  1. Division of Molecular Pharmaceutics (M.B.D., B.M.K.) and Division of Pharmacotherapy and Experimental Therapeutics (D.R.T.), UNC Eshelman School of Pharmacy; and Department of Pathology and Laboratory Medicine, School of Medicine (A.S.B.), The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
  1. Address correspondence to:
    Dr. Dhiren R. Thakker, UNC Eshelman School of Pharmacy, CB#7355, 100L Beard Hall, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599-7360. E-mail: dhiren_thakker{at}unc.edu
  • ↵1 Current affiliation: Department of Clinical Pharmacology, Genentech, Inc., San Francisco, California.

View Full Text

Statistics from Altmetric.com

Article usage

Article usage: January 2013 to January 2021

AbstractFullPdf
Jan 20134540159
Feb 20134592077
Mar 20133681046
Apr 20131671527
May 20131061022
Jun 201362518
Jul 2013751324
Aug 201339931
Sep 201365310
Oct 201383827
Nov 201344617
Dec 201339615
Jan 20144125
Feb 20142913
Mar 2014743034
Apr 2014322616
May 2014332522
Jun 20141886
Jul 2014311613
Aug 2014121313
Sep 2014201516
Oct 201421138
Nov 2014211315
Dec 2014301615
Jan 2015143114
Feb 201510195
Mar 2015172316
Apr 2015162410
May 2015223017
Jun 2015143218
Jul 201583111
Aug 20151162
Sep 201511144
Oct 201512127
Nov 2015161016
Dec 201515258
Jan 2016152112
Feb 201652220
Mar 201652826
Apr 2016136416
May 201664318
Jun 2016163526
Jul 2016113610
Aug 2016333411
Sep 20169714
Oct 201619718
Nov 20166727
Dec 2016520721
Jan 2017011019
Feb 201745714
Mar 201728710
Apr 201719111
May 20172448
Jun 201744019
Jul 201712315
Aug 201714712
Sep 20171347
Oct 20170418
Nov 201715814
Dec 20171429
Jan 201816311
Feb 201826112
Mar 201814318
Apr 201823914
May 201844315
Jun 201815414
Jul 201814313
Aug 201804411
Sep 201814720
Oct 201804218
Nov 201823317
Dec 201829137
Jan 20193300
Feb 20193635
Mar 20192784
Apr 201942715
May 20192928
Jun 20192327
Jul 20192723
Aug 20192425
Sep 201917411
Oct 20194413
Nov 20194903
Dec 20194832
Jan 20202710
Feb 20201632
Mar 20203208
Apr 20202248
May 20202000
Jun 20203900
Jul 20202802
Aug 2020313
Sep 20201633
Oct 20201624
Nov 20202143
Dec 20202801
Jan 20211762

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 41 (3)
Drug Metabolism and Disposition
Vol. 41, Issue 3
1 Mar 2013
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
P-Glycoprotein Increases Portal Bioavailability of Loperamide in Mouse by Reducing First-Pass Intestinal Metabolism
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Enhancement of the Bioavailability of Loperamide by P-gp

Matthew B. Dufek, Beverly M. Knight, Arlene S. Bridges and Dhiren R. Thakker
Drug Metabolism and Disposition March 1, 2013, 41 (3) 642-650; DOI: https://doi.org/10.1124/dmd.112.049965

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Enhancement of the Bioavailability of Loperamide by P-gp

Matthew B. Dufek, Beverly M. Knight, Arlene S. Bridges and Dhiren R. Thakker
Drug Metabolism and Disposition March 1, 2013, 41 (3) 642-650; DOI: https://doi.org/10.1124/dmd.112.049965
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Candesartan glucuronide serves as a CYP2C8 inhibitor
  • Role of AADAC on eslicarbazepine acetate hydrolysis
  • Gene expression profile of human intestinal epithelial cells
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics